We aim to be a leading biotech company providing unique, innovative products addressing high unmet medical needs in the fields of orthopaedics and bone diseases.

**Value Drivers**
- Off-the-shelf solutions
- Large, underserved patient populations
- Later-stage clinical validation
- Competitive, scalable, proprietary cell therapy manufacturing process

**Key Facts**
- Clinical pipeline across 3 indications
- Product candidates entering Phase II/III development
- Strong IP portfolio, proprietary cell therapy manufacturing process and know-how

**Mission**

**Ambitions**
- Advancing innovation in orthopaedic care
- Progressing the pipeline through Phase II/III development towards commercialization
- Partnerships for co-development and commercialization

**Clinical Pipeline**

**Advancing Innovation in Orthopaedic Care**
2 Products entering Phase II/III end 2019

**Allob**
- Differentiated, active bone-forming cells
- Allogeneic (from healthy donor bone marrow)
- Injectable (minimally invasive)
- Economical, large-scale manufacturing
- Off-the-shelf (ready to use)
- Market:
  - Delayed-union fractures (~700K patients p.a.)
  - Spinal fusion procedures (~500K patients p.a.)

**JTA-004**
- Patented composition of 3 active substances
- Convenient, single injection
- Analgesic & lubricating properties
- Better pain reduction vs market leader
- Simple manufacturing process
- Market:
  - Symptomatic knee osteoarthritis (~27M patients p.a. in EU/USA/JAP)

Bone Therapeutics is listed on Euronext Brussels and Euronext Paris with the ticker symbol “BOTHE” and ISIN code BE0974280126.

Analyst coverage:
- Hugo Solvet (Bryan, Garnier & Co)
- Sandra Cauwenberghs (KBC Securities)
- Arsene Guekam (Kepler Cheuvreux)

Headquarters and manufacturing
Rue Auguste Piccard 37
6041 Gosselies – Belgium
Phone: +32 (0) 71 12 10 00
Contact: info@bonetherapeutics.com

WWW.BONETHERAPEUTICS.COM